Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 10 patients early 2021 for 25 for Breakthrough Designation

<< Previous

Bullboard Posts

Next >>

Comment by Bungeon Mar 19, 2021 12:01pm

227 Views

Post# 32838216

RE:RE:RE:RE:RE:10 patients early 2021 for 25 for Breakthrough Designation

DJDawg wrote:
Hello, I'm newish to this company so I'm trying to understand the backstory around the treatments to date. I hear about 12 or 15 patients. I hear about some being excluded, some being undertreated, some being retreated correctly. I saw on one discussion some patients being removed from the data but that those patients were actually doing well so could have kept them. It is all very confusing. Is this information found anywhere on the Theralase website?

It's hard to get answers with TLT sometimes.

Failure to Communicate

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs